Caspofungin as First-Line Therapy for the Treatment of Invasive Aspergillosis After Thoracic Organ Transplantation
- 1 January 2008
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (1) , 1-6
- https://doi.org/10.1016/j.healun.2007.10.002
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Mediastinal Mass Due to Aspergillus fumigatus After Lung Transplantation: A Case ReportThe Journal of Heart and Lung Transplantation, 2005
- Post-lung transplantation Aspergillus niger infectionThe Journal of Heart and Lung Transplantation, 2005
- Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2005
- A survey of anti-fungal management in lung transplantationThe Journal of Heart and Lung Transplantation, 2004
- Risk Factors of Invasive Aspergillosis after Heart Transplantation: Protective Role of Oral Itraconazole ProphylaxisAmerican Journal of Transplantation, 2004
- Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesCancer, 2003
- Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive AspergillosisAntimicrobial Agents and Chemotherapy, 2002
- Aspergillosis Case-Fatality Rate: Systematic Review of the LiteratureClinical Infectious Diseases, 2001
- Editorial Response: Estimating the True Cost of Amphotericin BClinical Infectious Diseases, 1999
- Itraconazole in opportunistic mycoses: Cryptococcosis and aspergillosisJournal of the American Academy of Dermatology, 1990